Chimeric antigen receptor T-cell therapy—CAR T for short—has been a major advance in treating blood cancers like leukemia and ...

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...

Often diagnosed when surgery is no longer an option, pancreatic cancer is one of the most difficult cancers to treat and has ...

A new CAR T-cell therapy attacks supportive cells in the tumor microenvironment that bear the surface protein, uPAR.

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...

ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable residual disease (MRD)-negative responses in the first four patients with relapsed ...

The consistency of results across racial groups suggests that, within the controlled setting of clinical trials, ...

Diffuse intrinsic pontine glioma (DIPG) is one of the most devastating pediatric brain tumors. It sits in the brainstem where it cannot be surgically removed, responds poorly to chemotherapy, and ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...